Nautilus Biotechnology (NAUT) Receivables (2026)
Nautilus Biotechnology (NAUT) posted Receivables of $100000.0 for Q2 2026.
Nautilus Biotechnology (NAUT) Receivables (2026) Analysis & Trends
Nautilus Biotechnology has reported Receivables for 1 years, with the latest figure at $100000.0 in Q2 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | - |
| 10 | Nautilus Biotechnology | 122.05 Mn | 122.05 Mn | 175,000.00 | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |